Shilpa Medicare Submits First Patch Product Dossier in Europe for Rotigotine

Greetings from Shilpa Medicare Limited…!

Shilpa Medicare is proud to announce its first transdermal patch product dossier submission in Europe for Rotigotine, a leading therapy for Parkinson’s disease. Expected approval is anticipated by Q3 2025, following robust bioequivalence studies. Rotigotine, a top-selling product globally, offers advanced treatment for the symptoms of Parkinson’s and is poised to strengthen Shilpa’s market presence.

About Shilpa Medicare Limited

Shilpa Medicare Limited, a leader in the global pharmaceutical industry for over 30 years, focuses on “Innovating for Affordable Healthcare.” Our vertically integrated operations encompass the full pharmaceutical value chain, including APIs, finished formulations, biologics, transdermal patches, and oral films.

With nine manufacturing plants, five R&D centers, and four analytical labs, we adhere to the highest quality standards, certified by global regulatory agencies such as the USFDA, EMA, WHO-GMP, and ANVISA Brazil.

Shilpa Medicare is committed to improving patient outcomes through high-quality, affordable medicines, supported by a team of over 4,000 professionals. We aim to create a healthier, sustainable future through innovative products, partnerships, and social responsibility.

Contact

For further information or partnership opportunities, please contact us at:

• Madhav S: Madhav@vbshilpa.com
• Keshav S: Keshav@vbshilpa.com
• Hanumanth R: Hanumanth@vbshilpa.com